{"id":147,"date":"2024-09-19T22:50:34","date_gmt":"2024-09-19T22:50:34","guid":{"rendered":"http:\/\/stage.aftpharm.com\/us-en\/?page_id=2"},"modified":"2026-02-26T02:33:00","modified_gmt":"2026-02-26T02:33:00","slug":"about","status":"publish","type":"page","link":"https:\/\/www.aftpharm.com\/za-en\/about\/","title":{"rendered":"About us"},"content":{"rendered":"\n
\n
\n
\n
\n
What we do<\/h6>\n\n\n\n

Pharmaceuticals with a difference<\/h2>\n\n\n\n

With a guiding principle of working to improve your health, we deliver pharmaceuticals that make a real difference to people\u2019s health.<\/strong><\/h4>\n\n\n\n

AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. Our diverse range of products includes both proprietary and in-licensed items, which are available in more than 85 countries worldwide.<\/p>\n\n\n\n

We continue to invest in extending our global reach, expanding our product range, and adding new medicines to a research and development portfolio that promises better health outcomes for people around the world.<\/p>\n\n\n\n

AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) was established in early 2025 as part of our global expansion strategy. Jointly owned by AFT Pharmaceuticals (70%) and Edge Pharmaceuticals (30%), AFT SA is able to leverage both companies’ pharmaceutical products as well as Edge’s international expertise in accessing markets.<\/p>\n\n\n\n

Following its acquisition of the Hospital Division business of Pharma Dynamics (Pty) Ltd in October 2025, AFT SA now holds a SAHPRA[1] licence and offers a portfolio of more than 30 trusted hospital products. From 2026 onward, it will expand access to a growing range of globally marketed therapeutics for South African hospitals and the wider community.
<\/p>\n\n\n\n

More about our history here<\/a><\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/span>
\n
\n

“At AFT Pharmaceuticals, we remain committed to reinvest into R&D to help people across the world.”<\/p>\n\n\n\n

Hartley Atkinson, Founder and Managing Director<\/p>\n<\/blockquote>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n
\n
\n
\n

South Africa Team<\/h2>\n<\/div>\n<\/div>\n\n\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Deon Hall <\/h2>\n
CEO of AFT Pharmaceuticals SA (Pty) Ltd<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Drew Hansen <\/h2>\n
Business Development Executive<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Sanette Benecke <\/h2>\n
Responsible Pharmacist<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Sharon Jordaan <\/h2>\n
Supply Chain Co-Ordinator<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
View all staff<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\n

The Board<\/h2>\n\n\n\n

Our board members<\/h4>\n<\/div>\n\n\n\n
\n
\n
View all staff<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n \"About\n <\/div>\n
\n
\n

\n David Flacks <\/h2>\n
AFT Pharmaceuticals Chair<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Dr Hartley Atkinson <\/h2>\n
CEO, Managing Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Marree Atkinson <\/h2>\n
Chief of Staff, Executive Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Andrew Lane <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Dr Ted Witek <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n
\n
\n \"About\n <\/div>\n
\n
\n

\n Allison Yorston <\/h2>\n
Independent Director<\/div>\n <\/div>\n Profile<\/span><\/i><\/a>\n <\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
View all staff<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n
\n
\n

Join our team<\/h2>\n\n\n\n

We\u2019re always looking for talented people, please have a look at the careers we currently have available.<\/h4>\n\n\n\n
\n
Careers<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>
\"\"<\/figure><\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
\n\n\n
\n
\n

Latest news<\/h2>\n\n\n\n

Keep up to date with the latest news from AFT Pharmaceuticals<\/h4>\n<\/div>\n\n\n\n
\n
\n
View All News<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
\n
\n
\n
\n \"\" <\/div>\n
\n
\n

November 28, 2025<\/p>\n

AFT Pharmaceuticals SA acquires the Hospital Division of Pharma Dynamics<\/h2>\n

AFT Pharmaceuticals SA (Pty) Ltd (\u2018AFT SA\u2019) announces it has successfully completed the acquisition of the Hospital Division business of Pharma Dy…<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n

\n
\n \"\" <\/div>\n
\n
\n

November 20, 2025<\/p>\n

AFT delivers 10th consecutive first half revenue increase<\/h2>\n

AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today reports a strong first-half performance for the six months to 30 September 2025, with revenue growing 3…<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n

\n
\n \"\" <\/div>\n
\n
\n

September 25, 2025<\/p>\n

On track for $300m FY27 revenue; positive iron IV study result<\/h2>\n

– Sales tracking in line with $300 million FY27 revenue target\r\n– Clinical trial supports the potential patient benefits of novel iron IV development …<\/p>\n <\/div>\n Read More<\/a>\n <\/div>\n<\/div>\n <\/div>\n <\/div>\n\n